Results 281 to 290 of about 881,543 (309)

Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases

Nature Reviews Drug Discovery, 2012
Charles A Dinarello, Anna Simon, Jos W M Van Der Meer   +2 more
exaly  

Interleukin-1 antagonism in type 1 diabetes of recent onset: two multicentre, randomised, double-blind, placebo-controlled trials

Lancet, The, 2013
Antoinette Moran, Linda A Dimeglio, Stephen E Gitelman   +2 more
exaly  

INTERLEUKINS | IL-17

2006
Q. Hamid, S. Lajoie-Kadoch, S. Létuvé, Z. Müller   +3 more
openaire   +1 more source

Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study

Lancet, The, 2017
B G Feagan, Julian Panes, Arthur Kaser
exaly  

Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies

Lancet, The, 2012
Daniel F Freitag, John Gregson, Peter Willeit   +2 more
exaly  

The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis

Lancet, The, 2012
Daniel I Swerdlow, Michael V Holmes, Karoline B Kuchenbaecker   +2 more
exaly  

Interleukin-17 Family

2016
Yuping Lai, Chen Dong
openaire   +1 more source

Interleukin-21: a double-edged sword with therapeutic potential

Nature Reviews Drug Discovery, 2014
Warren J Leonard, Rosanne Spolski
exaly  

Tumour necrosis factor α and interleukin 1β in relapse of Crohn's disease

Lancet, The, 1999
Jochen Hampe
exaly  

Interleukin-17

2006
openaire   +1 more source